Slide 1: 9M and Q3 2023 Results
9M and Q3 2023 Results Conference call and webcast for investors and analysts 9th November 2023
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Conference call agenda
9M and Q3 2023 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Dave Fredrickson Susan Galbraith EVP, Oncology Business EVP, Oncology R&D BioPharmaceuticals Ruud Dobber Sharon Barr EVP, BioPharm
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Benefitting from broad-based, diverse sources of revenue
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Benefitting from broad-based, diverse sources of revenue Strong commercial performance Broad-based, diverse source of and financial delivery in 9M 2023 Total Revenue Total Revenue | +5% Core EPS | +17%
Slide 6: Strong growth across regions, therapy areas
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Strong growth across regions, therapy areas Strong growth across Oncology, CVRM, R&I Double-digit growth across US, EM and EU 9M Total Revenue ex-COVID-19 (USD millions) and Growth vs PY and Rare Disea
Slide 7: AstraZeneca – building the pipeline of the future
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks AstraZeneca – building the pipeline of the future Delivering sustainable, industry-leading growth CELL THERAPY GENE THERAPY EPIGENETICS T-CELL ENGAGERS NOVEL ADCs IO BISPECIFICS OLIGONUCLEOTIDES RNA TH
Slide 8: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER
Slide 9: 9M 2023 – Reported profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks 9M 2023 – Reported profit and loss 9M 2023 CER change % Total Q3 2023 CER change % Total $m % Revenue $m % Revenue Total Revenue 33,787 5 100 11,492 6 100 - Product Sales 32,466 4 96 11,018 5 96 - Alli
Slide 10: 9M 2023 – Core profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks 9M 2023 – Core profit and loss 9M 2023 CER change % Total Q3 2023 CER change % Total $m % Revenue $m % Revenue Total Revenue 33,787 5 100 11,492 6 100 - Product Sales 32,466 4 96 11,018 5 96 - Alliance
Slide 11: Cash Flow, Net Debt and 2023 Financial Guidance
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Cash Flow, Net Debt and 2023 Financial Guidance Continued EBITDA improvement Net Debt bridge Updated 2023 Guidance (CER) $bn Total Revenue • Mid single-digit % increase (previously low-to-mid single-di
Slide 12: Capital allocation
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Capital allocation Capital allocation strategy unchanged Investments to drive future growth • Currently >120 projects in Phase II/III development Reinvestment in the business • Investments behind launc
Slide 13: AstraZeneca – AI in Commercial
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks AstraZeneca – AI in Commercial DRIVING FASTER, BETTER DECISION MAKING| harnessing technology to deliver better patient outcomes Delivering real-time insights Addressing unmet needs and personalising en
Slide 14: Oncology
Oncology Dave Fredrickson ONCOLOGY BUSINESS Susan Galbraith ONCOLOGY R&D
Slide 15: Oncology – 9M and Q3 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – 9M and Q3 2023 Total Revenue +20% in 9M 2023 fueled by strong global demand growth Oncology Q3 2023: key dynamics 9M 2023 $13.5bn, +20% 5,000 • Tagrisso +6%, continued ADAURA and FLAURA glob
Slide 16: Oncology – Tagrisso and Calquence
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – Tagrisso and Calquence Leading value propositions, commercial execution reinforce future growth opportunity Establishing Tagrisso for every EGFRm patient Calquence maintaining BTKi leadershi
Slide 17: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights Data at WCLC and ESMO reinforce AstraZeneca leadership across tumour types Consolidating leading position Expanding into new tumour Dato-DXd beat conventional in EGFRm lung |
Slide 18: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights Volrustomig leading new wave of immuno-oncology bispecific molecules Encouraging early phase data for volrustomig Four bispecific Phase III first-in-class monovalent bispecifi
Slide 19: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights Establishing AstraZeneca portfolio of differentiated ADCs Five wholly owned ADCs already in the clinic AZD0901 Clinical stage trials ongoing in lung, breast, haematology, GYN/
Slide 20: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights In-house development and strategic collaborations expand our reach in cell therapy Advancing T-cell receptor therapies Innovative armoured CAR-T programme for solid tumour acq
Slide 21: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D
Slide 22: BioPharmaceuticals – 9M and Q3 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – 9M and Q3 2023 CVRM Total Revenue +19% in 9M 2023 and strong launch brand momentum in R&I CVRM R&I V&I 9M 2023 $7.9bn, +19% 9M 2023 $4.7bn, +9% 9M 2023 $944m 3,000 2,500 1,800 2,50
Slide 23: BioPharmaceuticals – 9M and Q3 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – 9M and Q3 2023 Portfolio evolution enables long-term sustainable growth Key R&I medicines grew Tezspire market leadership Farxiga - substantial growth 42% in Q3 2023 within first y
Slide 24: BioPharmaceuticals – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – R&D highlights Advancing potential novel medicines to address unmet needs across CKD and HF Uncontrolled Hypertension1 Resistant Hypertension1 potential 4 ~37m ~12m baxdrostat new
Slide 25: BioPharmaceuticals – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – R&D highlights Data at ASN and ERS publication support Phase III trials zibotentan / dapagliflozin tozorakimab | IL-33 mAb Chronic Kidney Disease with high proteinuria RAGE/EGFR ST
Slide 26: BioPharmaceuticals – obesity with ECC5004
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals Accelerating presence in obesity with ECC5004, a novel once-daily oral GLP-1RA ECC5004 (GLP-1RA) Significant market opportunity in obesity global development and commercialisation ri
Slide 27: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION
Slide 28: Rare Disease – 9M and Q3 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – 9M and Q3 2023 Strong double-digit growth in 9M 2023 with Total Revenue +12%, momentum into year-end Total Revenue by medicine Total Revenue by region 9M 2023 $5.8bn, +12% C5 franchise i
Slide 29: Rare Disease – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – R&D highlights Advancing expansion of Ultomiris in nephrology Ultomiris Data supports initiation of Phase II SANCTUARY trial in IgAN potential Phase III trial Mean spot UPCR over rapid,
Slide 30: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 31: AstraZeneca
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks AstraZeneca Focused investment in pipeline of the future, rich near-term Phase III catalyst flow Near-term rich catalyst flow through 2024 EGFRm NSCLC LAURA (unresectable Stg. III) H1 2024 HER2-low DES
Slide 32: Question & Answer Session
Question & Answer Session Pascal Soriot Aradhana Sarin Marc Dunoyer E XE CUTIVE DIRE CTOR & E XE CUTIVE DIRE CTOR & CHIE F E XE CUTIVE OFFICE R, CHIE F E XE CUTIVE OFFICE R CHIE F FINANCIAL OFFICE R ALE XION Susan Galbraith Dave Fredrickson Sharon Barr E XE CUTIVE VICE PRE SIDE NT, E XE CUTIVE VICE
Slide 33: Appendix
Appendix ▪ Pipeline Highlights ▪ Oncology tumour maps ▪ Emerging Markets performance ▪ Key medicines performance by therapy area
Slide 34: Delivering on science-led innovation
AP P E ND I X | Pipeline Highlights Delivering on science-led innovation Selected key pipeline highlights since Q2 2023 Results Oncology BioPharmaceuticals Rare Disease 3 Breakthrough Designations (US): 6 regulatory approvals in major markets, including: Tagrisso Lynparza (JP) Forxiga (CN) EGFRm NSC
Slide 35: AstraZeneca in Lung Cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in Lung Cancer Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 metastatic resectable Stg. I-III unresectable Stg. I-II Stg. III 1L 2L+ Leading the future of Est. epi (G7) ~200K ~30K ~70K ~350K ~290K lung cancer treatm
Slide 36: AstraZeneca in Breast Cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death established SoC Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7) 540k 125k 90k 65k 55k Enhertu ± THP NST→ residual disease → HER2-positiv
Slide 37: AstraZeneca in Breast Cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7) 405k 80k 65k 55k 50k Current SoC drives Camizestrant to replace ET good outcomes for pat
Slide 38: Emerging Markets – 9M 2023
AP P E ND I X | Emerging Markets Emerging Markets – 9M 2023 Total Revenue +10% at CER to $9.2bn, +20% at CER ex-COVID-19 medicines 4,000 3,500 3,000 2,500 Total Revenue ($m) 2,000 1,500 1,000 500 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2022 2023 China Emerging Markets ex-China COVID-19 medicines 38 Growth
Slide 39: Oncology
AP P E ND I X | 9M 2023 Product Performance Oncology Tagrisso Imfinzi and Imjudo 10% growth at CER to $4,380m in 9M 2023 56% growth at CER to $3,102m in 9M 2023 1,600 1,200 1,400 1,000 1,200 Total Revenue ($m) Total Revenue ($m) 1,000 800 800 600 600 400 400 200 200 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 0 Q3
Slide 40: Oncology
AP P E ND I X | 9M 2023 Product Performance Oncology Lynparza Lynparza 3% decrease at CER to $2,070m in 9M 2023 Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential 600 800 700 600 Product Sales ($m) 400 Collaboration Revenue ($m) 500 400 300 200 200 100 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q
Slide 41: Oncology
AP P E ND I X | 9M 2023 Product Performance Oncology Calquence Enhertu 26% growth at CER to $1,839m in 9M 2023 >2x growth at CER to $919m in 9M 2023 700 400 600 350 300 Total Revenue ($m) Total Revenue ($m) 500 250 400 200 300 150 200 100 100 50 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 42: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
AP P E ND I X | 9M 2023 Product Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 41% growth at CER to $4,389m in 9M 2023 Stable at CER at $996m in 9M 2023 49% growth at CER to $300m in 9M 2023 1,800 400 120 1,600 350 100 1,400 300 Total Revenue ($m) Total R
Slide 43: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | 9M 2023 Product Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Breztri Tezspire 13% growth at CER to $1,134m in 9M 2023 73% growth at CER to $478m in 9M 2023 >5x growth at CER to $230m in 9M 2023 450 180 100 400 160 90 350 140 80 Total Revenue ($m) Total Revenue ($m
Slide 44: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | 9M 2023 Product Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Pulmicort 1% decrease at CER to $1,842m in 9M 2023 10% growth at CER to $493m in 9M 2023 800 300 700 250 600 Total Revenue ($m) Total Revenue ($m) 200 500 400 150 300 100 200 50 100 0 0 Q3 Q4 Q1 Q2 Q3
Slide 45: Rare Disease
AP P E ND I X | 9M 2023 Product Performance Rare Disease Soliris Ultomiris Strensiq 15% decrease at CER to $2,429m in 9M 2023 58% growth at CER to $2,141m in 9M 2023 24% growth at CER to $847m in 9M 2023 1,200 900 350 800 300 1,000 700 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 250 800